New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2014
07:27 EDTKWR, ETM, CASH, ALNY, GSVC, EPAM, BMTC, CUBI, FARO, EGHT, AMEEmerald Advisers to hold a forum
21st Groundhog Day Investment Forum is being held in Philadelphia on Feburary 6.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 30, 2015
08:17 EDTEGHT8x8, Inc. awarded new communications patent by USPTO
8x8, Inc. announced that it has been awarded a new patent related to its communication technologies, along with a patent that was acquired as part of the acquisition of the assets of Quality Software Corporation, which closed on June 18, 2015. On July 28, 2015, the U.S. Patent and Trademark Office issued United States Patent number 9,094,488 entitled “Remote Management of VoIP Device Contact Lists.” The ‘488 patent relates to an apparatus for providing Voice-over-IP services to and configuring contact lists for a plurality of VoIP-enabled devices. As part of the Quality Software Corporation transaction, 8x8 has also acquired United States Patent number 8,811,593 entitled “Call Center Agent Centric Speech Decoding System and Method with Quality Assurance Function.” The ‘593 patent relates to, among other things, displaying questions and answers (Q&A) to a call center agent based upon the decoding of agent speech using a basic Q&A database and an agent database, each with key words or phrases.
July 29, 2015
16:56 EDTFAROFARO Technologies reports Q2 EPS 24c, consensus 24c
Subscribe for More Information
16:05 EDTFAROFARO Technologies appoints Laura A. Murphy as CFO
Subscribe for More Information
07:57 EDTCUBICustomers should recover after fraud found to be isolated, says Janney Capital
Janney Capital noted investors were "clearly concerned" about the potential for significant additional fraud losses at Customers Bancorp after it recorded a $6M loss provision related to a potential fraud as part of its Q2 results, but the firm thinks the company's subsequent announcement that it believes the event was isolated should help ease those concerns. Janney said it expects the shares to recover from their selloff and keeps a Buy rating and $32 fair value estimate on Customers' shares.
July 28, 2015
16:24 EDTCUBICustomers Bancorp's internal investigation concludes fraud was isolated event
Customers Bancorp, the parent company of Customers Bank, announced that its internal investigation has concluded that the previously reported fraudulent transaction that resulted in Customers taking a special $6M specific reserve in the Q2 was an isolated event. "Our Risk Management, Loss Prevention, Credit and Finance teams have been working continuously since Wednesday, July 22, when the potential fraud was detected by the Company," stated the company. "This type of thorough review was productive as it also identified two process and policy improvements that Customers Bank has already implemented that will minimize the chances of a similar fraud ever being committed in the future. We also looked at our collateral for this credit and believe the $6M specific reserve is adequate and was a prudent move by Customers," company continued.
07:25 EDTALNYAlnylam Pharmaceuticals to hold a roundtable
Subscribe for More Information
07:20 EDTEPAMEPAM Systems multiple aligned with sustainable growth, says UBS
UBS remains confident that EPAM Systems' multiple is aligned with its sustainable growth target of mid-20%. The firm expects a slight beat from Q2 earnings with its NavigationArts acquisition an opportunity to leverage its depth and scale in complex engineering. UBS reiterated its Buy rating and raised its price target to $87 from $81 on EPAM Systems shares.
July 27, 2015
08:05 EDTALNYAlnylam initiates Phase 1/2 clinical trial for ALN-AAT
Alnylam Pharmaceuticals (ALNY) has initiated a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease. The Phase 1/2 trial will be conducted initially in normal healthy volunteers, and, then, in patients with alpha-1 liver disease. Initiation of this trial is based on encouraging pre-clinical data presented at the Digestive Disease Week meeting May 16 – 19, 2015. The company expects to present initial clinical data from this trial in early 2016. ALN-AAT is a subcutaneously administered investigational RNAi therapeutic that utilizes Alnylam’s proprietary ESC-GalNAc-siRNA conjugate delivery technology. ESC-GalNAc-siRNA conjugates are designed to achieve targeted delivery of RNAi therapeutics to hepatocytes through uptake by the asialoglycoprotein receptor, and enable subcutaneous dosing with increased potency and durability and a wide therapeutic index. As per the filed CTA, the Phase 1/2 trial of ALN-AAT is a randomized, single-blind, placebo-controlled study being conducted in three parts. Parts A and B are single-dose and multi-dose, dose-escalation studies, designed to enroll up to a total of 48 healthy adult volunteers. Part C will be a multi-dose study designed to enroll up to a total of 24 adults with alpha-1 liver disease and mild-to-moderate liver fibrosis. The primary objective of the study is to evaluate safety and tolerability of single and multiple subcutaneous doses of ALN-AAT. Secondary objectives include evaluation of pharmacokinetics and clinical activity for ALN-AAT as measured by knockdown of serum AAT. In addition, biopsies will be obtained from subjects with alpha-1 liver disease to quantify the effects of treatment on levels of periodic acid-Schiff-stained globules, a measure of misfolded AAT accumulation observed in the livers of alpha-1 liver disease patients. In January 2014, Alnylam and Genzyme, a Sanofi (SNY) company, formed an alliance to accelerate and expand the development and commercialization of RNAi therapeutics across the world. The alliance is structured as a multi-product geographic alliance in the field of rare diseases. Alnylam retains product rights in North America and Western Europe, while Genzyme obtained the right to access certain programs in Alnylam's current and future Genetic Medicines pipeline, including ALN-AAT, in the rest of the world. In certain defined instances, Genzyme has co-development/co-commercialization and/or global product rights. Genzyme's rights are structured as an opt-in that is triggered upon achievement of human proof-of-principle.
July 23, 2015
17:33 EDTBMTCBryn Mawr Bank reports Q2 non_GAAP EPS 50c, consensus 53c
Reports Q2 net income of $8.1M, up 6.8% from $7.6M for the same period in 2014. Reports Q2 net interest income $25.1M, up $5.6M or 28.9% from $19.4M for the same period in 2014. The increase in net interest income between the periods was largely related to the interest income generated by loans acquired in the merger with Continental Bank Holdings. Reports Q2 loan loss provision $850K vs. ($100K) a year ago. Reports Q2 net charge-offs ($187K) vs. ($200K) a year ago.
10:34 EDTCUBICustomers Bancorp sees FY16 EPS $2.40-$2.60, consensus $2.16
Subscribe for More Information
10:34 EDTCUBICustomers Bancorp sees FY15 EPS excl items to be over $2.00, consensus $1.99
Subscribe for More Information
09:55 EDTCUBICustomers Bancorp trading halted, pending news
Subscribe for More Information
07:29 EDTALNYAlnylam to hold a roundtable
Subscribe for More Information
05:13 EDTCUBICustomers Bancorp reports Q2 EPS 39c, consensus 50c
Reports Q2 tangible book value per share $17.28.
July 22, 2015
16:13 EDTEGHT8x8, Inc. backs FY16 revenue view $202M-$206M, consensus $203.36M
Subscribe for More Information
16:12 EDTEGHT8x8, Inc. reports Q1 EPS ex one time payment 4c, consensus 3c
Reports Q1 revenue $47.9M, consensus $46.31M. Excluding a one-time technology license payment, revenue increased 23% year over year to $46.7M. The company reported a one-time $1.2M accelerated technology license payment during Q1. Average monthly service revenue per business customer increased 20% to $353, compared with $293 in the same period last year.
July 20, 2015
08:05 EDTALNYAlnylam initiates Phase 3 open label extension study with patisiran
Alnylam announced that it has initiated its Phase 3 open-label extension study, abbreviated APOLLO-OLE, with patisiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of TTR-mediated amyloidosis in patients with Familial Amyloidotic Polyneuropthy. All patients who complete the APOLLO Phase 3 trial with patisiran are eligible to enroll in APOLLO-OLE. The study will evaluate the long-term safety and efficacy of patisiran and will also measure effects of treatment toward a number of clinical endpoints, including the modified Neuropathy Impairment Score, or “mNIS+7,” which is an evaluation of muscle weakness, sensory and autonomic function, and nerve conductance. The company is also reiterating its previous guidance that – assuming positive study results in the APOLLO Phase 3 study – it expects to be in a position to file a New Drug Application for patisiran in the 2017 timeframe.
July 17, 2015
17:07 EDTBMTCBryn Mawr Bank announces resignation of CFO
Subscribe for More Information
10:05 EDTCUBIOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:59 EDTCUBICustomers Bancorp initiated with a Buy at Janney Capital
Target $32.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use